Quoin Pharmaceuticals, Ltd., a late stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company’s lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). It also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat Netherton Syndrome; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.
Metrics to compare | QNRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipQNRXPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.4x | −5.7x | −0.5x | |
PEG Ratio | 0.00 | −0.11 | 0.00 | |
Price/Book | 0.7x | 3.2x | 2.6x | |
Price / LTM Sales | - | 10.3x | 3.3x | |
Upside (Analyst Target) | - | 176.9% | 43.5% | |
Fair Value Upside | Unlock | −4.0% | 6.3% | Unlock |